Loading stock data…
Embecta Corp (EMBC)
$5.55-0.25 (-4.31%)
After Hours$5.55+0.00 (+0.00%)· Last close Sep 8
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Embecta Corp. in the Healthcare sector is trading at $5.55 with a market capitalization of $183M. Wall Street consensus targets $4.00 (2 analysts), implying a -27.9% move over the next 12 months. The stock is currently 64% below its 52-week high of $15.55, remaining 26.6% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply -27.9% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $271.70M↑ | $221.80M↓ | $261.20M↓ | $264.00M↓ | $295.50M |
| Gross Profit | $153.30M↑ | $127.80M↓ | $161.70M↑ | $158.50M↓ | $197.10M |
| Operating Income | $64.30M↑ | $42.90M↓ | $76.30M↑ | $64.30M↓ | $105.00M |
| Net Income | $21.10M↑ | -$4.10M↓ | $44.10M↑ | $26.40M↓ | $45.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection device...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$183.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
8.11%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.87%
Volume
Today's trading volume
1.35M
Recent News
Embecta (EMBC) Q3 2026 Earnings Call Transcript
Revenue fell 8.1% year-over-year, but margin guidance rose for fiscal 2026.
Embecta Corp. Q3 2026 Earnings Call Summary
Moby summary of Embecta Corp.'s Q3 2026 earnings call
Embecta Corp (EMBC) (Q3 2026) Earnings Call Highlights: Strong Sequential Recovery and Raised ...
Embecta Corp (EMBC) beats expectations with a $50 million sequential revenue jump, raises adjusted EPS guidance, and advances its Owen Mumford integration despite persistent U.S. market pressures.
Embecta Q3 Earnings Call Highlights
Embecta (NASDAQ:EMBC) reported fiscal third-quarter 2026 revenue of approximately $272 million, down 8.1% from the prior-year period on a reported basis and down 8.9% on an adjusted constant-currency basis. The company said results improved sequentially from the fiscal second quarter, with revenue r
Embecta (EMBC) Stock Fair Value Moves Lower As Analysts Reset Medtech Expectations
Embecta is in focus after one fair value estimate was reset from US$15.00 to US$4.00, which highlights how much some analysts have reworked their view of what the stock might be worth under updated assumptions. That shift sits alongside commentary pointing to a tougher setup for medtech valuations, higher inflation and capital flowing toward data center stocks, all of which are shaping how investors think about Embecta today. As you read on, you will see what is driving this evolving...